31 Jan 2023 IQVIA and Alibaba Cloud Partner to Provide Commercial and Clinical Solutions in China Press Releases
30 Jan 2023 Takeda Receives Global (Excluding China) Exclusive License for Fruquintinib, a Highly Selective Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor, from Hengrui Medicine Press Releases
30 Jan 2023 Menarini Group Subsidiary Stemline Therapeutics Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer Press Releases
30 Jan 2023 Escient Pharmaceuticals Receives FDA Approval to Begin Phase 1 Clinical Trial of EP262, an Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders Press Releases
30 Jan 2023 FDA Grants Orphan-Drug Exclusivity to Xeris Biopharma’s Recorlev® Press Releases CHICAGO–(
30 Jan 2023 FDA Approves Guardant Health’s Guardant360® CDx as Companion Diagnostic for Menarini Group’s ORSERDU™ to Treat Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer Press Releases …
30 Jan 2023 Phase 3 Clinical Trial of Datopotamab Deruxtecan and Pembrolizumab in Previously Untreated Metastatic Non-Small Cell Lung Cancer Patients Begins with TROPION-Lung07 Study Press Releases
